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Abstract
Background: Few studies have examined outcomes for children treated for multidrug-resistant tuberculosis (MDR-TB),
including those receiving concomitant treatment for MDR-TB and HIV co-infection. In Lesotho, where the adult HIV
seroprevalence is estimated to be 24%, we sought to measure outcomes and adverse events in a cohort of children treated
for MDR-TB using a community-based treatment delivery model.
Methods: We reviewed retrospectively the clinical charts of children #15 years of age treated for culture-confirmed or
suspected MDR-TB between July 2007 and January 2011.
Results: Nineteen children, ages two to 15, received treatment. At baseline, 74% of patients were co-infected with HIV, 63%
were malnourished, 84% had severe radiographic findings, and 21% had extrapulmonary disease. Five (26%) children had
culture-confirmed MDR-TB, ten (53%) did not have culture results available, and four (21%) subsequently had results
indicating drug-susceptible TB. All children with HIV co-infection who were not already on antiretroviral therapy (ART) were
initiated on ART a median of two weeks after the start of the MDR-TB regimen. Among the 17 patients with final outcomes,
15 (88%) patients were cured or completed treatment, two (12%) patients died, and none defaulted or were lost to follow-
up. The majority of patients (95%) experienced adverse events; only two required permanent discontinuation of the
offending agent, and only one required suspension of MDR-TB treatment for more than one week.
Conclusions: Pediatric MDR-TB and MDR-TB/HIV co-infection can be successfully treated using a combination of social
support, close monitoring by community health workers and clinicians, and inpatient care when needed. In this cohort,
adverse events were well tolerated and treatment outcomes were comparable to those reported in children with drug-
susceptible TB and no HIV infection.
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Introduction
Between 2000 and 2009, there have been an estimated five
million new cases of multidrug-resistant tuberculosis (MDR-TB),
defined as resistance to isoniazid and rifampicin. 3.5 million
patients received no treatment or treatment of unknown quality,
and 1.5 million died [1]. An estimated 10% to 15% of these
patients were children [2]. Pediatric MDR-TB is often a result of
primary resistance transmitted from adults with MDR-TB, rather
than secondary resistance acquired as a result of suboptimal
therapy [3,4]. Thus, unlike adult MDR-TB prevalence, which
often reflects the failure of national TB control programs, pediatric
MDR-TB surveillance reveals ongoing transmission of MDR-TB
in the community.
Pediatric tuberculosis presents several unique diagnostic and
treatment challenges. Treatment delay is particularly problematic
for children with MDR-TB, and outcomes are poor when
treatment is delayed [5,6]. Because of the difficulty of obtaining
sputum from young children [7] and their tendency to have
paucibacillary TB [6,7], children are less likely to have culture
confirmation of TB [8–10]. Thus, drug-susceptibility testing (DST)
is often not possible [5], and the decision to initiate second-line TB
therapy in children with clinical and radiographic evidence of TB
disease must be made based on the patients’ TB history [11–13].
Additional challenges arise when diagnosing and managing
MDR-TB in the context of HIV co-infection. Poor response to
first-line TB treatment in HIV co-infected patients can occur for
reasons other than drug resistance, including poor adherence and
the presence of other opportunistic infections with pulmonary
manifestations, and HIV co-infected patients are at increased risk
of recurrent TB infections [14,15]. Moreover, patients failing first-
line TB treatment are often hospitalized in facilities lacking in
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with circulating drug-resistant TB strains or transmitting TB to
others. Outbreaks of MDR-TB among HIV patients in health
facilities have been well-documented [16–21], including a
nosocomial outbreak in a pediatric ward [22]. Additionally,
optimal timing of antiretroviral therapy (ART) initiation relative to
second-line TB therapy is unknown [23]. Patients on treatment for
both HIV and MDR-TB face a high pill burden, and little is
known about the frequency and severity of adverse events from
concomitant treatment, particularly in children [22–24].
A small number of studies and case series have examined
outcomes for children treated for MDR-TB [6,25–32]. Taken
together, these suggest that when appropriate treatment–including
individualized regimens and strong supervision and support–is
initiated early, favorable treatment outcomes can be achieved in
pediatric MDR-TB patients. However, there are few reports of
DR-TB/HIV co-treatment in pediatric patients [22,30,31].
We sought to describe the clinical features, treatment course,
and final outcomes in a cohort of children treated for MDR-TB in
Lesotho using a community-based treatment delivery model.
Methods
Ethics Statement
As this was a retrospective study of medical information
previously collected in the course of routine clinical care, informed
consent was not required. This study was approved by the Partners
HealthCare Human Research Committee.
Setting
Lesotho is a small, mountainous country completely surrounded
by South Africa, with a population of approximately 1.8 million.
Lesotho has a high burden of both HIV and TB: 24% of the adult
population is HIV infected [33], and the estimated prevalence of
TB is 402 cases per 100,000 population [34]. Among TB patients,
an estimated 77% are co-infected with HIV [34]. Since 2007, the
Lesotho Ministry of Health and Social Welfare (MOHSW), with
support from Partners In Health, has operated a national MDR-
TB program offering comprehensive, community-based treat-
ment, free of charge to patients and their families. Partners In
Health is a non-governmental organization that has worked in
partnership with local communities and governments to provide
health care access to a combined population of 2.4 million people
in 12 countries, including more than 13,000 MDR-TB patients in
Peru, Russia, Kazakhstan, and Lesotho [35].
Study Design
We conducted a retrospective analysis of medical charts of all
patients ages 15 years or younger who initiated second-line TB
treatment for confirmed or suspected MDR-TB between July 27,
2007 and January 1, 2011. We excluded one patient who began an
MDR-TB regimen and was subsequently switched to first-line
tuberculosis treatment based on drug-susceptibility testing (DST)
results, patient history, and clinical and radiographic response to
MDR-TB treatment.
Treatment Strategy
Treatment protocols, including pediatric dosing, followed
international standards of care [25,36–38]. In general, patients
were referred by clinicians working in the MOHSW network of
hospitals and health centers to the Lesotho national MDR-TB
program for evaluation of confirmed or suspected MDR-TB. At
the time of initial evaluation, sputum or lymph node specimens
were collected and sent for DST. While awaiting DST results, a
child was initiated on an empiric regimen with second-line TB
drugs if he or she met the following criteria: 1) the child had
clinical and radiographic evidence of TB disease, and 2) the child
was either a household contact of a patient with confirmed or
presumed MDR-TB, or the child had failed at least one supervised
first-line regimen. The protocol for initiating empiric treatment
has been described in detail previously [39]. Empiric regimens
consisted of six drugs–pyrazinamide, capreomycin (or kanamycin),
levofloxacin (or moxifloxacin or ofloxacin), ethionamide (or
prothionamide), cycloserine, and para-aminosalicylic acid (PAS).
When DST results of the patient or household source case were
available or when a patient had received second-line drugs
previously, treatment regimens were modified accordingly.
The management of patients who were started empirically on
MDR-TB treatment and subsequently had DST results indicating
susceptibility to isoniazid and rifampicin was considered on an
individual case-by-case basis. Based on the patient’s clinical
history, duration of MDR-TB treatment, and treatment response,
the clinical team decided whether to transfer the patient to the
local health center to receive first-line TB treatment or maintain
the patient on the second-line regimen with the addition of
rifampicin and high-dose isoniazid.
Lesotho experienced an uninterrupted supply of second-line
antituberculous drugs during the study period. Because none of
antituberculous drugs used in the standard regimen were available
in pediatric formulations, patients were provided with adult
formulations, and the clinicians and community health workers
instructed caregivers to divide doses and cut tablets into the
appropriate size.
Patients with unknown HIV serostatus were offered testing at
the first visit. All patients with HIV co-infection who were not yet
receiving ART were initiated on an ART regimen as soon as they
were tolerating the MDR-TB treatment regimen, regardless of
CD4 cell count. The standard ART regimen consisted of two
nucleoside reverse transcriptase inhibitors (zidovudine or stavudine
plus lamivudine) and one non-nucleoside reverse transcriptase
inhibitor (efavirenz, or nevirapine for children under three years of
age). All patients received pyridoxine supplementation to prevent
peripheral neuropathy [40].
MDR-TB treatment was provided in the community for
patients in stable, ambulatory condition. Trained, paid community
health workers (CHWs) delivered second-line antituberculous
drugs and antiretroviral therapy twice-daily under direct observa-
tion. The CHWs also monitored patients daily for adverse events.
Routine laboratory monitoring–including full blood count, liver
function tests, electrolytes, and creatinine–was performed monthly
at clinic visits, and a specialist clinician evaluated patients at these
visits. Thyroid-stimulating hormone (TSH) was initially measured
within the first six months of MDR-TB treatment initiation and
subsequently every four to six months. Patients with at least one
TSH result elevated above 10.0 mIU/l were initiated on a weight-
based dose of levothyroxine, which was continued until one month
after completion of MDR-TB therapy; TSH was monitored
throughout the treatment period at regular intervals [41]. Patients
with a serum potassium value below 3.5 mmol/l received
potassium and magnesium supplementation until normalization
of serum potassium. Patients experiencing nausea or vomiting
were treated with prochlorperazine. Chest radiographs were taken
at baseline, every six months, and at treatment completion, and
the clinical team attempted to obtain sputum samples for culture
of M. tuberculosis at baseline and at each monthly clinic visit.
A community team communicated regularly between the clinics
and the community, tracking patients who missed any appoint-
ment and assessing the stability of each patient’s household
Pediatric MDR-TB Outcomes in Lesotho
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caregivers with counseling about MDR-TB and HIV, food
supplements, reimbursement for treatment-related transportation,
and other types of psychosocial support as needed. Patients who
were clinically unstable or experienced severe adverse events were
admitted to Botsabelo Hospital, a specialized MDR-TB inpatient
facility in the capital (Maseru).
Data Collection and Analysis
Baseline characteristics, treatment history, and clinical signs and
symptoms, including radiographic findings, laboratory values,
adverse events, and treatment outcomes, were abstracted from
patient records and entered into a Microsoft Access 2003
(Microsoft Corporation, Redmond, WA) database. Standard
definitions for retrospective MDR-TB analyses were used to
determine final treatment outcomes [42]. Cure was defined as five
consecutive negative cultures at least 30 days apart in the final 12
months of treatment, and treatment failure was defined as two or
more positive cultures in the final year of treatment or a positive
result for any of the final three cultures. Patients were designated
treatment completed if they completed treatment according to
national protocol but did not meet the definition of cure or
treatment failure. Data were analyzed using SAS 9.2 (SAS
Institute, Cary, NC).
Results
Nineteen children were included in this analysis (Table 1). At
the start of treatment, their ages ranged from two to 15 years old,
with a median age of eight years (Table 2). The cohort was
characterized by a high prevalence of baseline malnutrition (63%),
stunting (63%), HIV co-infection (74%), and severe radiographic
findings (cavitary lesions or bilateral disease) (84%). Fifty-three
percent of the patients had received two or more previous courses
of TB treatment prior to referral. All patients presented with
pulmonary manifestations of TB infection, and four patients
presented with concurrent extrapulmonary TB (three cases of
miliary TB and one case of tuberculous lymphadenitis). Ten
patients (53%) were smear-negative at the time of MDR-TB
treatment initiation. Figure 1 shows the baseline culture and DST
results of the 19 patients.
Patients were treated with a median of six antituberculous drugs
(range, 5 to 9). Sixteen patients (84%) were hospitalized at
treatment initiation for a median of 1.5 months (range, 0.5 to 9)
(Table 3). Most of these patients did not have a clinical indication
for hospitalization at treatment initiation, but were hospitalized
because of unstable household situations and other social
problems. Among the 18 patients who completed the intensive
phase of treatment, the parenteral agent (kanamycin or capreo-
mycin) was administered for a median of nine months (range, 8 to
12).
Final outcomes were available for 17 patients: 15 patients (88%)
had treatment success (seven patients cured and eight patients
completed treatment) and two patients (12%) died (Table 3). Both
patients who died (case 3 and 16) were co-infected with HIV.
These two children showed significant clinical improvement on
second-line TB therapy, including substantial weight gain and an
end of TB symptoms. During the eighteenth month of treatment,
case 3 arrived at the MDR-TB hospital with severe dyspnea and
died the next morning of an unknown cause. Case 16 missed her
clinic visit in the twelfth month of treatment, and tracking by the
community team revealed that the patient had died at home of an
unknown cause. No patients defaulted or were lost to follow-up.
The two patients currently on treatment have exhibited favorable
responses to MDR-TB therapy.
Eighteen patients (95%) experienced at least one adverse event
(Table 4). Most adverse events were mild to moderate in severity
and were successfully managed without suspending treatment
(Table 4). The most common adverse events were hypothyroidism
(79%), hypokalemia (68%), and nausea or vomiting (53%). One
patient who had been on ART for more than two years
experienced elevated liver enzymes two weeks after initiation of
MDR-TB treatment (case 9). MDR-TB treatment was suspended
until transaminitis resolved, and after five weeks, the MDR-TB
regimen was reintroduced without pyrazinamide. In another
patient, cycloserine was permanently discontinued due to vision
problems (case 8).
Among the 14 patients with HIV co-infection, the median
(interquartile range [IQR]) CD4 cell count at the start of MDR-
TB treatment was 486.5 (49.3–714.8) cells/mm
3 (Table 3). Eight
patients were already on ART at the start of the MDR-TB
regimen, and the remaining six patients were started on ART a
median of 13.5 days after the MDR-TB regimen. The median
(IQR) increase in CD4 cell count during MDR-TB treatment was
397 (276.5–622) cells/mm
3, and the median (IQR) weight gain
among HIV co-infected patients was 4 (3–6) kg. There were no
incidences of immune reconstitution inflammatory syndrome
(IRIS) after ART initiation. Three patients were switched from
zidovudine to stavudine when they experienced anemia, and one
patient was switched from stavudine to zidovudine after the onset
of peripheral neuropathy. Another patient who had experienced
immunological deterioration prior to MDR-TB treatment was
switched from a second-line ART regimen to a first-line regimen
when genotypic resistance testing revealed no mutations confer-
ring resistance to first-line antiretroviral drugs.
Discussion
Our results demonstrate that, even in a setting of high HIV
prevalence, it is possible to achieve favorable outcomes among
children treated for MDR-TB using early empiric treatment
delivered through a comprehensive community-based program.
The latter included referral to inpatient care as needed. Almost
90% of the children treated experienced cure or treatment
completion, despite the geographically challenging setting and the
high rate of baseline malnutrition, severe lung damage, and co-
infection with HIV. Excluding the four patients who subsequently
had DST results suggesting drug-susceptible TB, the mortality rate
among confirmed and suspected MDR-TB cases in this study was
13%. Our outcomes were similar to outcomes among children in
MDR-TB treatment programs with largely HIV-negative patients,
where treatment success rates have ranged from 80 to 100% and
crude mortality rates, from 0 to 6% [25–28,32].
In contrast to the favorable outcomes achieved in low HIV
prevalence settings, pediatric case series with a high prevalence of
HIV have reported lower rates of treatment success [6,30]. Both of
these case series included only culture-confirmed MDR-TB cases,
which may imply more extensive diseases at baseline. One study in
South Africa reported final outcomes for 31 children treated for
confirmed MDR-TB, of whom six were HIV co-infected and 10
were not tested [6]. Twenty-one children (68%) were cured, four
(13%) died, and six (19%) defaulted after at least five months of
treatment. However, the study was conducted before ART
became available in South Africa. Another study from South
Africa reported 12-month outcomes for 13 children with MDR-
TB, of whom seven were co-infected with HIV and six received
ART [30]. In that report, four children died a median of 2.8
Pediatric MDR-TB Outcomes in Lesotho
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PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37114months after submitting sputum for culture and DST, including
three co-infected children who were unstable at treatment
initiation. Of the remaining nine patients, two defaulted, one
patient exhibited radiological deterioration, and six showed
improvement by 12 months. Delay in the initiation of appropriate
treatment likely played a role in the poor outcomes. Patients
initiated MDR-TB treatment a median of 2.5 months after
submitting sputum, and three of 13 patients died or defaulted
before initiating appropriate treatment.
Two recent studies of DR-TB and HIV co-infected children
treated concurrently with ART and second-line TB treatment
have reported more favorable outcomes [22,31]. Four pediatric
XDR-TB patients with HIV co-infection were successfully cured
with co-treatment in South Africa [22]. Another study in South
Africa examined outcomes in 111 children with MDR-TB,
including 43 children with HIV co-infection, most of whom
initiated ART prior to or during MDR-TB treatment. In that
report, 82% of patients achieved favorable outcomes, and five of
the 13 deaths occurred before confirmation of MDR-TB and
initiation of appropriate treatment [31].
In contrast to previous reports on co-infected children, children
in the Lesotho program were initiated on empiric second-line TB
treatment immediately after evaluation for suspicion of MDR-TB,
without waiting for DST confirmation. Treatment delay is
particularly problematic among children because of the difficulty
in obtaining sputum and the high likelihood of paucibacillary TB.
In a study of 39 children with MDR-TB in South Africa, Schaaf et
al. found that treatment delay (the time from when MDR-TB
should have been clinically suspected until the initiation of
treatment) was a median of two days if the DST of the source
case was considered and 246 days if the DST of the source case
was not considered [6]. For HIV-infected pediatric patients,
guidelines recommend prompt initiation of second-line TB
treatment using the index case’s DST results if TB disease
develops in a child in close contact with an index case with drug-
resistant TB [25,26,28,43].
MDR-TB should be suspected when a child has been in contact
with a TB patient who died while on treatment and who was
suspected to have had MDR-TB [25,26]. Six children in our case
series had household contact with individuals suspected, but not
confirmed, of having MDR-TB. The household source cases had
either been initiated on empiric MDR-TB treatment as high-risk
MDR-TB suspects or had experienced clinical deterioration of
their tuberculosis and died while receiving first-line TB treatment.
Given the poor outcomes associated with delayed initiation of
treatment, our clinicians initiated empiric second-line therapy in
these children.
Efforts to obtain sputum samples for culture and DST
confirmation for all pediatric patients were aggressive. Clinicians
attempted to collect sputum specimens at monthly clinic visits, and
gastric lavage and sputum induction were used for young children.
For the diagnosis of extrapulmonary MDR-TB, pleural fluid
Table 2. Baseline characteristics (N=19).
Characteristic No. of Patients (%) Median (Range)
Male 10 (53)
Age (years) 8 (2–15)
Weight-for-age, z-score
a 21.90 (23.72 to +0.17)
Height-for-age, z-score
a 22.71 (26.36 to +2.58)
Malnutrition
b 12 (63)
Stunting
c 12 (63)
HIV co-infection 14 (74)
Cavitary lesions or bilateral disease on chest radiograph 16 (84)
Extrapulmonary TB concurrent with pulmonary TB 4 (21)
Number of previous treatments None 1 (11)
One 7 (37)
Two 6 (32)
Three or more 5 (26)
No. of first- and second-line TB drugs exposed to previously 4 (0–6)
Baseline bacteriologic results Smear-positive and culture-positive 7 (37)
Smear-positive and culture-negative 2 (11)
Smear-negative and culture-positive 1 (5)
Smear-negative and culture-negative 8 (42)
Smear-negative and no culture result 1 (5)
DST results available 9( 4 7 )
Household contact with laboratory-confirmed MDR-TB patient 3 (16)
Household contact with suspected MDR-TB patient 6 (32)
Orphan Lost one parent 4 (21)
Lost two parents 7 (37)
aBased on the US Centers for Disease Control and Prevention (CDC) clinical growth charts [63].
bDefined as weight-for-age of ,5th percentile according to US CDC clinical growth charts.
cDefined as height-for-age of ,5th percentile according to US CDC clinical growth charts.
doi:10.1371/journal.pone.0037114.t002
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37114sample and lymph node aspirates are the only non-pulmonary
specimens routinely collected and cultured in Lesotho. Compared
with adults, children with TB are more likely to have extrapul-
monary TB [7,44]. However, all patients included in this report
had pulmonary involvement. As a result of limited diagnostics for
the detection of extrapulmonary TB in this setting, those without
pulmonary involvement were likely to have been missed.
Moreover, an unusually high proportion of patients had bilateral
disease or cavitary lesions, which is not associated with the classic
pediatric presentations of TB [44], raising the possibility that
significant numbers of children with less severe pulmonary disease
may have been undetected.
The five patients with culture-confirmed MDR-TB all experi-
enced cure or treatment completion. Of the other 14 patients, six
had household contact with a confirmed MDR-TB patient or
high-risk MDR-TB suspect, and the remaining patients had failed
to respond to at least one previous course of first-line TB
treatment. For several patients who initiated an empiric MDR-TB
regimen, subsequent DST results indicated susceptibility to
isoniazid and rifampicin. However, all had responded well to
MDR-TB treatment, experiencing significant clinical and radio-
logical improvement, after having been unsuccessfully treated with
at least one first-line TB regimen, so the clinical team decided to
continue them on MDR-TB treatment with the addition of
rifampicin and high-dose isoniazid. We did not have data on
patients’ adherence to previous courses of first-line TB treatment,
and it is possible that non-adherence, despite directly observed
therapy, may have contributed to failure of first-line treatment.
Additionally, three of the four patients had HIV co-infection,
making them susceptible to other potential causes of clinical
deterioration during first-line TB treatment [45]. Nevertheless, the
clinical team decided it was prudent to continue these four patients
on a modified version of the second-line regimen to which they
had responded clinically.
Although we were striving to provide rapid and appropriate
care to these patients, we note that the majority (58%) of the
children in our cohort had already received two or more previous
regimens of first-line TB drugs, and all but one of the household
contacts had been treated previously with first-line drugs,
suggesting that there was a delay in recognizing them as MDR-
TB suspects and initiating them on appropriate treatment.
Additionally, nearly half of the HIV co-infected patients were
not receiving ART at the time of MDR-TB treatment initiation,
despite the fact that pulmonary TB is a criteria for initiating ART
in the clinical staging of HIV/AIDS (irrespective of CD4 cell
count) [46–48].
Children with HIV co-infection who were not already on ART
were initiated on ART as soon as they were tolerating MDR-TB
treatment, as early as one week post initiation. Optimal time to
introduce ART following the start of TB treatment is uncertain, as
early introduction of ART after initiation of TB treatment is
believed to be associated with higher risk of IRIS [49,50].
However, literature on IRIS in adults suggests that mortality from
TB-associated IRIS is rare [51,52], and earlier initiation of ART
has been shown to significantly reduce mortality among severely
immunosuppressed adults receiving first-line treatment for drug-
susceptible TB [53]. The literature on IRIS in children treated for
TB is limited to a small number of case reports and case series
[54–57]. In a study in South Africa, data from 290 children on
ART were analyzed for the clinical presentation and outcome of
Figure 1. Baseline bacteriologic results for pediatric patients treated for MDR-TB. Note: H: isoniazid; R: rifampicin; DST: drug-susceptibility
testing.
a One patient (case 19) was culture-negative at baseline but later had DST results, indicating susceptibility to all drugs tested, from a positive
culture in the tenth month of treatment.
doi:10.1371/journal.pone.0037114.g001
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37114TB [55]. The authors concluded that the poor outcomes among
children who started ART within two months of TB treatment was
due to the more advanced HIV disease in this group; the early
introduction of ART was rarely (,10% of cases) associated with
drug-related adverse events or IRIS. In our program in Lesotho,
children responded well to concurrent ART and MDR-TB
treatment, with few regimen changes required, no defaults, and
no episodes of IRIS observed.
In this cohort, children experienced a higher incidence of
adverse events compared to other reports [8,25,26,32]. Nearly
80% of patients experienced hypothyroidism a median of 75 days
after MDR-TB treatment initiation. Recent studies from South
Africa have also reported high rates of abnormal thyroid function
tests (.50%) among children treated for MDR-TB [58,59].
Although hypothyroidism is a known side effect of ethionamide/
prothionamide and PAS, recovery from non-thyroidal illness
syndrome (NTIS) could also cause a transient TSH elevation in
children with TB or HIV infection. However, TSH was elevated
.20 mIU/l in eleven patients, and seven patients experienced
prolonged TSH elevation lasting more than three months,
suggesting primary hypothyroidism rather than recovery from
NTIS.
Patients in this study also experienced a high incidence of
hypokalemia (68%), which occurred a median of 39 days after the
start of the MDR-TB regimen. In adults, electrolyte disturbances,
including hypokalemia, have been attributed to the use of
aminoglycosides and capreomycin [60,61]. Low serum potassium
may also result from severe malnutrition or diarrhea and vomiting
caused by antituberculous agents, such as PAS, or chronic
gastrointestinal infections common among HIV patients. Nearly
one-third of patients experienced ototoxicity with a median onset
of 265 days after initiating MDR-TB treatment. Since audiometry
was performed only to confirm patient or caregiver self-report of
hearing loss, this likely represents an underestimate, and routine
audiometry should be considered for all children receiving
treatment for MDR-TB.
Although ART drugs and second-line TB drugs have potential
overlapping or additive toxicities [24], it is not clear that HIV co-
infection or concurrent ART could explain the higher incidence of
adverse events in the cohort, as adverse events were common
among both HIV-infected and HIV-uninfected patients. We
suspect that the high degree of malnutrition and poor clinical
status at baseline may have played a role. Patients were monitored
closely at both the community and clinic level, and adverse events
were managed aggressively [37,41,60].
Table 3. Treatment of MDR-TB and HIV disease.
Characteristic N (%) or Median (range or IQR)
MDR-TB Treatment (N=19)
Hospitalization at initiation – n (%) 16 (84)
Length of hospitalization, mo – median (range) 1.5 (0.5–9)
No. of drugs in regimen – median (range) 6 (5–9)
Time on parenteral agent, mo (N=18)
a – median (range) 9 (8–12)
Time to culture conversion, days (N=7) – median (range) 53 (37–105)
Time to smear conversion, days (N=8) – median (range) 51.5 (32–93)
Final outcomes (N=17) – n (%) Cured 7 (41)
Completed treatment 8 (47)
Died 2 (12)
Antiretroviral Treatment (N=14)
Baseline CD4 cell count (cells/mm
3) – median (IQR) 486.5 (49.3–714.8)
Increase in CD4 cell count (cells/mm
3) during MDR-TB
treatment – median (IQR)
397 (276.5–622)
Baseline weight (kg) – median (IQR) 16.5 (15–22)
Increase in weight (kg) during MDR-TB treatment – median (IQR) 4 (3–6)
On ART at MDR-TB treatment initiation – n (%) 8 (57)
Started ART after MDR-TB treatment initiation – n (%) 6 (43)
Time to ART initiation after start of MDR-TB regimen (days)
(N=6) – median (range)
13.5 (8–70)
Initial ART regimen concurrent with MDR-TB treatment – n (%) AZT, 3TC, EFZ 9 (64)
D4T, 3TC, EFZ 3 (21)
D4T, 3TC, NVP 1 (7)
DDI, ABC, RTV/LPV 1 (7)
ART regimen changes during MDR-TB treatment – n (%) AZT switched to D4T due to anemia 3 (21)
D4T switched to AZT due to peripheral neuropathy 1 (7)
DDI, ABC, RTV/LPV switched to AZT, 3TC, EFZ
following genotypic resistance testing
1 (7)
Note: IQR: interquartile range; AZT: zidovudine, 3TC: lamivudine, D4T: stavudine, EFZ: efavirenz, DDI: didanosine, ABC: abacavir, RTV: ritonavir, LPV: lopinavir.
aAmong patients who completed the intensive phase of treatment.
doi:10.1371/journal.pone.0037114.t003
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the CHWs and community team provided close monitoring of the
patients’ household situation and psychosocial needs. Many
patients had been orphaned by HIV and TB (Table 2), and some
had been neglected by their caregivers. The community team
helped school-aged children to return to school and assisted
families without income to start income generating activities.
Providing for these psychosocial needs likely helped to achieve
zero defaults and favorable treatment outcomes.
The favorable outcomes reported in this study are particularly
notable because they were achieved in a predominately ambula-
tory setting. Because of the complexity of managing MDR-TB and
HIV co-infection, the traditional model of MDR-TB treatment in
this region of the world has been hospital-based care, and many
children with MDR-TB continue to be hospitalized unnecessarily.
The community-based treatment model minimized the risk of
nosocomial transmission of MDR-TB, which is particularly
important in high HIV prevalence settings like Lesotho. Our
findings demonstrate that good MDR-TB outcomes in the context
of HIV are achievable using a community-based model. However,
successful implementation of community-based care in this
geographically challenging setting where many patients live in
rural, mountainous areas required several key elements, including
strong links between the community team and clinicians, well-
trained and supervised CHWs, and reimbursement for travel
expenses related to treatment [62].
For children suspected of having MDR-TB disease, particularly
those with HIV co-infection, empiric second-line TB therapy
should be initiated while awaiting DST results. Patients with HIV
co-infection not already receiving ART may benefit from early
initiation of ART once the MDR-TB treatment regimen is
tolerated. Our community-based treatment delivery model
included empiric treatment, as well as close monitoring, frequent
routine screening, and timely interventions for adverse events.
Treatment outcomes for this strategy are comparable to those
reported among children with drug-susceptible TB and those
without HIV infection.
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